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Abstract
Cochlear gene therapy can be a new avenue for the treatment of severe hearing loss by inducing regeneration or
phenotypic rescue. One necessary step to establish this therapy is the development of a safe and feasible
inoculation surgery, ideally without drilling the bony cochlear wall. The round window membrane (RWM) is
accessible in the middle-ear space, but viral vectors placed on this membrane do not readily cross the membrane
to the cochlear tissues. In an attempt to enhance permeability of the RWM, we applied hyaluronic acid (HA), a
nontoxic and biodegradable reagent, onto the RWM of guinea pigs, prior to delivering an adenovirus carrying
enhanced green fluorescent protein (eGFP) reporter gene (Ad-eGFP) at the same site. We examined distribution
of eGFP in the cochlea 1 week after treatment, comparing delivery of the vector via the RWM, with or without
HA, to delivery by a cochleostomy into the perilymph. We found that cochlear tissue treated with HA-assisted
delivery of Ad-eGFP demonstrated wider expression of transgenes in cochlear cells than did tissue treated by
cochleostomy injection. HA-assisted vector delivery facilitated expression in cells lining the scala media, which
are less accessible and not transduced after perilymphatic injection. We assessed auditory function by measuring
auditory brainstem responses and determined that thresholds were significantly better in the ears treated with
HA-assisted Ad-eGFP placement on the RWM as compared with cochleostomy. Together, these data demon-
strate that HA-assisted delivery of viral vectors provides an atraumatic and clinically feasible method to in-
troduce transgenes into cochlear cells, thereby enhancing both research methods and future clinical application.
Introduction
Future Therapies for preventing or curing deafness due toinner-ear diseases will likely require introduction of viral
vectors and other large therapeutic reagents into the cochlea.
Efficient and safe delivery of reagents into the cochlea is a
challenge, because the cochlea is encased in the temporal bone
and cannot be readily approached without surgery. Deliver-
ing a meaningful concentration of a reagent requires access to
the cochlear fluids, which is a surgical procedure in both
humans and experimental animals. In the human ear, that
access involves drilling the mastoid bone and opening a co-
chleostomy in the lateral wall of the cochlea or penetrating the
round window membrane (RWM). These invasive proce-
dures pose risks of perilymphatic fistula and other mechanical
damage to the cochlea.
Placing reagents in the middle ear using an intratympanic
approach would be much less traumatic, with the most ef-
fective placement being in the round window niche. The
RWM separates the middle-ear cavity and the scala tympani
(the cochlear compartment that contains sodium-rich peri-
lymph) and serves as a semipermeable membrane that can
selectively absorb and/or secrete molecules, depending on
factors such as size, electrical charge, and concentration
(Goycoolea and Lundman, 1997; Goycoolea, 2001). The
membrane functions as a barrier that most likely provides
protection for the inner ear, and may be one of the reasons
why recurrent otitis media does not usually lead to inner-ear
damage. Although the barrier provided by the RWM is im-
perative for maintenance and protection, it can also be a
viable route for atraumatic diffusion of therapeutic reagents
into the inner ear. Development of a novel drug-delivery
system that efficiently delivers a meaningful concentration of
therapeutic reagents into the inner-ear fluids via the RWM
could become a new avenue for the treatment of otological
diseases.
Therapeutic reagents could be introduced into the cochlea
for treating both hearing and balance diseases. The targets
could be sensory cells, nonsensory epithelial cells, neurons,
or any other cellular or extracellular element in the cochlea or
vestibular organs that can be manipulated for preventing
degeneration or enhancing repair and regeneration. The
types of reagents may include anti-inflammatory drugs,
growth factors (Iwai et al., 2006; Lee et al., 2007), small
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therapeutic molecules (Maeda et al., 2009), and gene vectors
(Staecker et al., 1998; Van de Water et al., 1999; Jero et al.,
2001; Aarnisalo et al., 2006). Some of these therapeutic re-
agents have been found to traverse the RWM when applied
onto the round window niche, either directly or infiltrated
through an absorbent such as Gelfoam. Anti-inflammatory
drugs such as dexamethasone are found at higher concen-
trations in the perilymph of animals when injected in-
tratympanically into the middle ear than when injected by
traditional systemic routes, which is most likely explained by
diffusion across the RWM (Salt and Plontke, 2005; Bird et al.,
2007; Plontke et al., 2008). Other reagents such as growth
factors and gene vectors do not readily cross the RWM
(Stover et al., 1999; Jero et al., 2001; Duan et al., 2004; Wimmer
et al., 2004), and therefore require the assistance of an ab-
sorbent that maintains the contact of the reagent with the
RWM and/or induces a transient increase in the perme-
ability of the RWM.
Hyaluronic acid (HA) is a viscous, high-molecular-weight,
nonsulfated glycosaminoglycan polysaccharide that is pres-
ent throughout epithelial, connective, and neural tissue. HA
is a nontoxic compound that is biodegradable over time. A
concentrated form of HA is used clinically in cosmetic and
ophthalmic surgeries and is used pharmaceutically as a
substrate for drug delivery. In the inner ear, HA has also
been used for cochlear implant surgeries as a lubricant to
decrease friction and facilitate safer and deeper insertion
of the electrode into the scala tympani (Lehnhardt, 1992;
Donnelly et al., 1995). More recently, HA has been used as a
substrate to deliver therapeutic molecules such as dexa-
methasone into the inner ear via the RWM (Selivanova et al.,
2003, 2005; Barkdull et al., 2007; Borden et al., 2010). The exact
mechanism of this enhanced delivery is not clearly identified.
Its hypothesized mechanisms include increased osmotic
pressure above the RWM (Bjurström et al., 1987; Bagger-
Sjöbäck, 1991; Bagger-Sjöbäck et al., 1993), enhanced mem-
brane permeability (Selivanova et al., 2003), and prolonged
contact due to the high viscosity of HA allowing reagents to
traverse the RWM (Chandrasekhar et al., 2000). In-
tratympanic injection of dexamethasone with HA produced
a higher concentration of dexamethasone in perilymph than
did intratympanic or systemic injection of dexamethasone
alone (Chandrasekhar et al., 2000; Borden et al., 2010). Clin-
ical trials using intratympanic administration of dexameth-
asone with HA for the treatment of refractory idiopathic
sudden deafness or Ménière’s disease have shown significant
improvement of auditory function without systemic or local
side effects (Gouveris et al., 2005; Selivanova et al., 2005).
These trials indicate that HA can be used safely and effi-
ciently as a drug-delivery system in the ear.
Delivery of most pharmacological reagents leads to a
short-term activity limited by the diffusion, stability, me-
tabolism, and clearance of the drugs. To obtain long-term
therapy, gene delivery may have an advantage, as it leads to
continued gene expression over time. Gene delivery is most
efficient via viral vectors, but these do not readily cross the
RWM (Stover et al., 1999; Jero et al., 2001; Duan et al., 2004;
Wimmer et al., 2004; Wang et al., 2011). As such, a reagent
that can increase the permeability of the RWM to viral vec-
tors is necessary. To investigate the potential use of HA for
facilitating the migration of viral vectors across the RWM, we
applied HA with an adenovirus carrying enhanced green
fluorescent protein (eGFP) reporter gene (Ad-eGFP) to the
RWM of normal guinea pigs. Subsequently, we evaluated
eGFP expression in cells lining the scala tympani and those
lining scala media (the cochlear compartment containing
potassium-rich endolymph). We also tested for changes in
auditory function. We compared these results with those
obtained by placing HA or Ad-eGFP alone on the RWM, and
with results from injection of Ad-eGFP into the perilymph
via cochleostomy. Our data demonstrate that ears treated
with HA-assisted Ad-eGFP transport through the RWM had
robust eGFP expression in cells lining the perilymphatic and
endolymphatic spaces, whereas little or no eGFP expression
was seen in ears treated with HA or Ad-eGFP alone. Animals
inoculated with Ad-eGFP into the perilymph via co-
chleostomy had transgene expression limited to cells lining
the perilymphatic space. Auditory function measurements
revealed that the combination of HA and Ad-eGFP applied
to the RWM induced less hearing loss after surgery than did
injection of Ad-eGFP through a cochleostomy.
Materials and Methods
Animals and groups
Animal care and handling were approved by the Uni-
versity of Michigan Institutional Committee on the Use and
Care of Animals and performed using accepted veterinary
standards. Twenty-five female or male pigmented guinea
pigs weighing 300–350 g were purchased from Elm Hill
(Chelmsford, MA). Each animal was tested for the presence
of Preyer’s reflex before being included in the study.
One set of 15 animals was processed for quantitative his-
tological assessment 7 days after inoculation. These animals
were divided into three groups according to the inoculation
procedure. The first group had HA-assisted Ad-eGFP inoc-
ulation via the RWM on the left ear and HA alone applied on
the RWM of the contralateral ear (seven animals). The second
group had Ad-eGFP alone applied on the RWM (three ani-
mals). The third group had Ad-eGFP inoculated without HA
via a cochleostomy made in the basal turn (five animals) and
no treatment in the contralateral ear.
The other set of 10 animals received physiologic assess-
ment by auditory brainstem response (ABR) threshold
measurements before and after inoculation, and was divided
into two groups according to the inoculation procedure. One
group consisted of guinea pigs receiving Ad-eGFP inocula-
tion with HA via the RWM on the left ear and HA alone on
the contralateral ear (five animals). The other group included
guinea pigs receiving cochleostomy inoculation of Ad-eGFP
without HA on the left ear (five animals). All cochleae in
each group were processed for whole-mount (surface prep-
aration) analysis for detecting reporter-gene expression.
ABR assessment
ABRs were assessed for each animal in both ears. The
thresholds were measured for three frequencies, 4, 12, and
20 kHz (tone bursts, 15-ms duration, 1-ms cos2-shaped rise-
fall times), as described previously (Yamasoba and Dolan,
1997). ABRs were assessed prior to the inoculation surgery
(baseline) and 14 days after the inoculation surgery. We
compared the threshold shift from baseline and 14 days.
Furthermore, we compared the threshold shifts between the
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HA-assisted Ad-eGFP inoculation, HA alone, and Ad-eGFP
without HA inoculated via cochleostomy. The mean at each
frequency was tested against an expected mean of zero by t
test. For each set of three frequencies for a given treatment
group, the observed p values were compared against the
appropriate sequential Bonferroni criterion to maintain a
criterion of p < 0.05 to infer statistical significance.
Inoculation surgeries and viral vectors
General anesthesia was induced with ketamine (40 mg/
kg) and xylazine (10 mg/kg). After the guinea pig was fully
sedated, postauricular incision was performed and the
anteroventral border of the left trapezius was teased away
from its insertion on the posterior aspect of the skull. The otic
bulla was opened, and the RWM niche could be visualized
under the surgical scope. One drop of 14 mg/ml HA (hya-
luronic acid sodium salt from rooster comb; Sigma H5388;
Sigma, St. Louis, MO) diluted in sterile saline, or commer-
cially provided 14 mg/ml Healon GV (Advanced Medical
Optics Inc., Santa Ana, CA) was placed onto the left ear
RWM niche. This concentration of HA was shown in a pre-
vious in vitro study (Kelly et al., 1999) to be efficient for the
gradual release of gentamicin. Ten minutes later, we care-
fully removed as much HA as possible with absorbents,
without perforating the membrane. Subsequently, we ap-
plied 5 ll of Ad-eGFP onto the left RWM using a micro-
cannula attached to a Hamilton syringe. This vector solution
was not removed from the RWM. The right ear RWM re-
ceived HA alone. We used this method of application to
minimize the dilution of viral particle concentration by
mixing with HA. Despite careful removal of the HA from the
RWM, small amounts of the reagent remained on the surface
of the RWM, allowing it to mix with the viral vector and
remain on the RWM surface. The highly viscous nature of
14 mg/ml HA makes it difficult to aspirate and mix evenly
with the viral vector without vigorous agitation, which de-
grades the vector. The adenovector, Adef.11D 1.0383 PU/
Ml · 1012, was constructed with the transgene driven by the
cytomegalovirus promoter (kind gift from GenVec, Inc.,
Gaithersburg, MD). As controls, we applied Ad-eGFP alone
or HA alone likewise onto the RWM. A cochleostomy was
made in the basal turn of the cochlea, and the inoculation of
5 ll of Ad-eGFP into the scala tympani was carried out as
described previously (Stover et al., 1999), except that a silicon
ball was not fixed to the tip of the cannula.
Immunohistochemistry and analysis
Seven days after inoculation of Ad-eGFP, the temporal
bones were extracted and cochlear tissues locally perfused
with 4% paraformaldehyde (PFA) and fixed further for 1 hr
in PFA. After a rinse in phosphate-buffered saline (PBS),
tissues were permeabilized with 0.3% Triton X-100 for
10 min. Alexa Fluor 594 phalloidin (Molecular Probes, Eu-
gene, OR) was used to stain F-actin (1:200 dilution in PBS) for
30 min to observe cytoarchitecture. After the tissue was
washed with PBS, the tissue was cut into four turns, mounted
onto glass slides, and cover-slipped with Fluoro-Gel with
TES buffer (Electron Microscopy Sciences, Hatfield, PA).
Slides were observed with a Leica DMRB epifluorescence
microscope (Leica, Eaton, PA), Zeiss LSM 510 confocal mi-
croscope (Carl Zeiss AG, Oberkochen, Germany), or Leica
MZ10F fluorescence stereomicroscope (Leica). Confocal im-
ages were acquired and processed with LSM Image Browser
(Carl Zeiss, Germany). Fluorescence stereomicroscopy was




We evaluated auditory function using ABR threshold
measurement following inoculation of Ad-eGFP with HA-
assisted RWM inoculation as compared with Ad-eGFP via
cochleostomy inoculation without HA. At 2 weeks after
treatment, we compared auditory thresholds to baseline (Fig.
1). Additionally, ABRs were measured after HA application
to the RWM (with no viral vector). Threshold shifts were
significantly greater at the higher frequencies (12 and
24 kHz) in ears inoculated with Ad-eGFP via cochleostomy in
comparison with ears inoculated with Ad-eGFP with HA via
the RWM. HA alone or Ad-eGFP with HA caused a mild
threshold shift of less than 10 dB at all tested frequencies (Fig.
1, white and gray bars). There were no statistical differences
between the ears treated by Ad-eGFP with HA and those
treated with HA alone. In ears inoculated with Ad-eGFP via
cochleostomy, the threshold shifts ranged from 20 to 40 dB
throughout all frequencies. These data suggest that (a) HA
alone, when applied on the RWM, does not induce
FIG. 1. Threshold shifts (means + standard error) of
groups treated with Ad-eGFP inoculation via cochleostomy
(black bars), HA alone on RWM (white bars), and HA-
assisted Ad-eGFP inoculation via RWM (gray bars), and
measured 2 weeks after inoculation, at 4, 12, and 20 kHz.
Ears inoculated with Ad-eGFP via cochleostomy had average
threshold shifts greater than 20 dB at each tested frequency,
with larger shifts at higher frequencies, and all three aver-
ages were significantly greater than zero ( p < 0.05 after se-
quential Bonferroni adjustment). Average threshold shifts of
ears treated with HA alone or HA with Ad-eGFP were less
than 10 dB and were not significantly different from zero.
Moreover, the average shifts induced by HA-assisted Ad-
eGFP inoculation were not significantly different from those
induced by HA alone, even at 4 kHz where the difference
between means was somewhat larger ( p > 0.5). In addition,
threshold shifts for HA-assisted Ad-eGFP inoculation via
RWM were statistically lower than in animals inoculated
with Ad-eGFP via cochleostomy at 12 kHz ( p < 0.05) and
20 kHz ( p < 0.01). For all groups, n = 5.
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significant threshold shift, (b) the vector does not induce a
threshold shift when placed on the RWM with HA, and (c) in
contrast, the process of infusing a viral vector via a co-
chleostomy does induce a significant threshold shift.
The influence of HA on transgene expression
Transgene expression of eGFP in ears inoculated with Ad-
eGFP with HA via the RWM was observed in cells residing in
both the endolymphatic and perilymphatic compartments. In
contrast, in ears inoculated with Ad-eGFP via a cochleostomy
with no HA, expression of eGFP was limited to cells lining
the scala tympani. A summary of transduced cells and tis-
sues is given in Table 1. The data show that HA-RWM ap-
plication of the viral vector resulted in gene expression in all
four cochlear turns as compared with cochleostomy, which
only facilitated expression in the lower two turns, and that
only HA-RWM application reached cells lining the scala
media.
In ears inoculated with Ad-eGFP with HA via the RWM,
eGFP-positive cells in the lining of scala media were detected
mostly in the basal turn, with more robust transduction to-
ward the RWM (Fig. 2axy, axz, ayz, and b). Transgene ex-
pression observed in the second turn was minimal (Fig. 2c),
and little or no gene expression could be observed in the
higher turns. Cell types demonstrating eGFP expression in
the scala media included outer hair cells, Deiters’ cells, inner
and outer pillar cells, and interdental cells (Fig. 2a–c). Inner
hair cells were not transduced. Transduction of cells and
structures lining the scala tympani and scala vestibuli was
seen not only in the basal and second turns, but in most cases
also in the third turn (Fig. 3a) or higher (Table 1; images not
shown).
In contrast, ears inoculated with Ad-eGFP alone (no HA)
via cochleostomy exhibited transgene expression only in
mesothelial cells and fibrocytes. Cells in the scala media were
not transduced, and the distribution of eGFP was limited to
the first two turns (Fig. 3b, third turn).
When HA was used along with the adenovirus vector,
transduced cell types and tissues consisted of mesothelial
cells, Reissner’s membrane, and fibrocytes in the osseous
spiral lamina and the spiral ligament (Fig. 3c–h). However,
the epithelium of the stria vascularis remained negative (Fig.
3c). Transduction was consistent and robust in the meso-
thelial cells (Fig. 3f). We assessed the outer hair cell loss in
five of the seven guinea pigs treated with HA-assisted Ad-
eGFP via the RWM. Outer hair cell loss was minimal and
averaged 3.5 cells in half of the basal turn of the cochlea.
Inner hair cells were mostly intact. Contralateral ears and
ears treated with HA alone (no viral vector) had no eGFP
expression. Animals that had Ad-eGFP alone applied to the
RWM showed no expression of eGFP transgene in any cell
type of the inner ear (data not shown). These observations
demonstrate that HA-assisted transgene delivery via the
RWM was most effective in transducing cells lining the scala
tympani. Nevertheless, the moderate degree of transduction
of cells in the scala media should provide an attractive target
for research involving transgene expression in supporting
cells and outer hair cells using the intratympanic approach.
Discussion
This study compared transgene expression of Ad-eGFP in
cochlear tissue after two gene-delivery methods: HA-assisted
delivery via the RWM and delivery via cochleostomy with-
out HA. Our results demonstrate that relative to the tradi-
tional cochleostomy method, which disperses viral particles
directly into the perilymph, HA-assisted gene delivery
caused less ABR threshold shift and greater transduction of
cochlear cells. With HA, eGFP expression could be observed
not only in the cells lining the scala tympani, but also in the
scala media. Biological side effects were minimal or absent in
ears with inoculated HA via the intratympanic approach.
Influence of HA-assisted inoculation
via the RWM on auditory function
Threshold shifts measured in the ears inoculated with
Ad-eGFP and HA on the RWM (intratympanic approach)
were less than 10 dB and not significantly greater than zero,
comparable to that in ears that had HA applied alone (con-
trol). This result, along with the intact hair cell morphology
we observed, indicated that the Ad-eGFP vector had little or
no side effects on auditory function. This is consistent with
previous observations of minimal disturbance of auditory
function caused by one application of adenovirus vectors
(Stover et al., 1999; Yagi et al., 1999; Venail et al., 2007). In the
ears inoculated with Ad-eGFP via cochleostomy, the
threshold shift was significantly elevated in comparison with
the shift with the HA-assisted inoculation of Ad-eGFP, with
larger shifts at the higher frequencies. Because the Ad-eGFP
itself has little effect on the ABR measurements, mechanical
damage inflicted by the cochleostomy is likely responsible
for the threshold shifts. This is consistent with previous re-
ports that have illustrated a correlation between the me-
chanical damage caused by the cochleostomy and elevated
Table 1. Number of Guinea Pig (GP) Ears




HA (n = 7)
Cochleostomy
(n = 5)
GFP distribution by turns
All 7 0
1 and 2, only 0 5
GFP distribution by tissue or cell type
Reissner’s membrane 7 5
Mesothelial cells 7 5
Spiral ligament cells 3 5




Inner sulcus 3 0
Interdental 3 0
Outer hair cell 3 0
Inner hair cell 0 0
The extent of eGFP-positive cells is broader with HA-assisted Ad-
eGFP inoculation compared with cochleostomy inoculation. The
transgene expression of HA-assisted Ad-eGFP inoculation in the
organ of Corti is distributed mainly in the basal turn. Inner hair cells
were not transduced. Ad-eGFP inoculated via cochleostomy dem-
onstrated expression predominantly in the cells lining the scala
tympani.
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threshold shifts (Carvalho and Lalwani, 1999; Stover et al.,
1999; Kanzaki et al., 2007; Venail et al., 2007). Therefore, the
HA-assisted inoculation is a substantially safer delivery
modality than traditional inoculations via cochleostomy.
Additionally, ears that will likely receive treatments using
HA will have severe hearing loss to begin with, and therefore
a potential for mild threshold shift caused by HA could be
considered an acceptable risk. However, more caution may
be necessary when HA is used in treatments that aim to
protect residual hearing.
Distribution of transgene expression in the cochlea,
HA versus cochleostomy
In ears inoculated with HA and Ad-eGFP via the RWM,
eGFP expression was observed in cells lining the perilymph
throughout all cochlear turns and in cells of the membranous
labyrinth in the lower two turns. In contrast, transgene ex-
pression in ears inoculated via cochleostomy showed a lim-
ited distribution of eGFP expression in the scala tympani in
the first two turns. These data suggest that the inoculation
via the RWM with HA allows the viral vector to spread
further into the inner ear than a cochleostomy inoculation.
The absence of transgene expression in the higher turns with
cochleostomy inoculation may be due to the opposing flow
of perilymph and cerebrospinal fluid toward the leaking
fenestra (Stover et al., 1999; Salt and Plontke, 2009). HA-
assisted inoculation may allow vectors to be distributed
throughout the cochlea without altering the natural passive
diffusion of the cochlear fluids. Therefore, the modality and
site of inoculation could determine the extent of transgene
expression in the inner ear. Modification of the co-
chleostomy, such as sealing the fenestra with HA (Salt and
Plontke, 2009) or using a slow regulated injection flow, may
allow the viral vector to proceed more efficiently into the
higher turns.
The transduction of cells in the organ of Corti and other
cells lining the scala media after HA-assisted delivery was
concentrated in the basal turn, but could be seen at low ef-
ficiency in the second turn. This may suggest that the
FIG. 2. Whole mounts of auditory epi-
thelium from the basal (a, b, d) and sec-
ond (c) cochlear turn after HA-assisted
Ad-eGFP inoculation via the RWM. eGFP-
positive cells (green) indicate transduc-
tion, and phalloidin (red) was used to
stain F-actin. (axy) Confocal images
showing outer hair cells (OHC), Deiters’
cells (arrowheads), and pillar cells (P)
with robust eGFP expression. (axz) Tan-
gential optical section through the first
row of outer hair cells showing eGFP ex-
pression. (ayz) A radial section showing
an eGFP-positive outer hair cell (*) adja-
cent to a pillar cell (P). (b) Confocal stack
of images showing eGFP expression in
interdental cells (IDC) in basal turn. (c)
Epifluorescence image showing the sec-
ond turn organ of Corti with intact cells
and normal organization pattern and a
transduced inner sulcus cell. (d) Epi-
fluorescence for actin (d), eGFP (d¢), and
merged (d†) showing eGFP in Deiters’
cells (arrowheads) and pillar cells (ar-
rows). Scale bars = 50 lm in a–c and 40 lm
in d.
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anatomical barrier between perilymph and endolymph is
more permeable near the hook area adjacent to the RWM in
guinea pigs, allowing higher titers of the vector to reach the
basal turn. The data could also reflect the concentration
gradient in the perilymph after inoculation, which is greatest
near the RWM; therefore, the highest likelihood of diffusion
across the basilar membrane will be at this end.
Defining endolymphatic barriers using HA
Transduction of cells that line the scala media, including
the organ of Corti, is an important outcome due to the
functional significance of these cells. Previous reports and
our data suggest that adenovirus-mediated transgene ex-
pression is absent in the organ of Corti after perilymphatic
FIG. 3. Transgene expression of eGFP
after HA-assisted Ad-eGFP inoculation
via the RWM (a, c–h) or Ad-eGFP inocu-
lation via cochleostomy (b) in cells lining
the scala tympani. (a) Mesothelial cells
and fibrocytes with eGFP expression,
third turn. (b) No eGFP expression was
observed in ears with Ad-eGFP inocu-
lated via cochleostomy (no HA) in upper
turns (third turn shown here). (c) Low-
magnification image of the stria vascularis
and spiral ligament. (d) Light microscopy
image of (c). (e) Reissner’s membrane
(RM) shows eGFP expression in the basal
turn. (f) Mesothelial cells line the scala
tympani; focal plane is lower than the
luminal surface of the organ of Corti. (g)
Connective tissue in spiral ligament
shows eGFP expression, third turn. (h)
Fibrocytes within the osseous spiral lam-
ina with eGFP expression, second turn. P,
pillar cells; IDC, interdental cells; SPL,
spiral ligament; SV, stria vascularis. Scale
bars = 50 lm for all images (paired images
are at same scale).
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inoculation (Stover et al., 1999; Venail et al., 2007; Konishi
et al., 2008). The spread of the vector from the perilymph to
the endolymphatic regions of the cochlea could be explained
by the ability of HA to enhance membrane permeability
(Selivanova et al., 2003), which may allow direct penetration
of the viral particles through the basilar membrane to reach
the endolymph. Another explanation could be that HA fa-
cilitates vectors crossing via the canaliculi perforantes into
the modiolus and from there to the endolymph. The finding
that the Reissner’s membrane can be transduced suggests
that the vectors reach the scala vestibuli. This could occur by
spread across the connective tissue in the spiral ligament.
The radial connection of the fluids between the scala tympani
and scala vestibuli has been demonstrated in previous re-
ports using ionic tracers (Salt et al., 1991a,b). Vectors entering
the scala vestibuli may be able to cross the Reissner’s
membrane with the assistance of HA. The exact mechanism
or pathway of viral vector spread in the cochlea in con-
junction with HA still needs to be elucidated.
Transfer of genes into hair cells is important for several
research goals, such as manipulating gene expression to
understand the roles of gene products in these cells. Gene
transfer into hair cells is also of clinical importance for de-
veloping procedures for hearing protection or for phenotypic
rescue in hereditary deafness cases. Previous work with
adenovirus vectors in mature normal mammals or prenatal
culture conditions has shown that the transduction was re-
stricted to supporting cells (Kanzaki et al., 2001; Ishimoto
et al., 2002; Excoffon et al., 2006; Venail et al., 2007). The
reason for the lack of hair cell transduction in these studies is
not clear and could be partly attributed to the inability of
adenoviruses to reach the receptors (e.g., coxsackie and ad-
enovirus receptor and integrins) on the luminal surface of the
hair cells. Our present data demonstrate that with HA-
assisted gene delivery, the first row of outer hair cells in the
basal turn could be transduced efficiently. One possible ex-
planation of this result could be that HA may partially
contribute to the removal or attenuation of components on
the apical surface of hair cells that prevent the attachment of
adenovirus to its receptors.
The transduction of supporting cells in the auditory epi-
thelium is especially important because these cells would
likely be the primary target for inducing hair cell regenera-
tion via transdifferentiation in deaf patients in the future
(White et al., 2006) and because more than half of hereditary
deafness patients have supporting cell mutations (Hildeb-
rand et al., 2008). The mesothelial cells lining the scala tym-
pani and fibrous tissue in the osseous spiral lamina could
also become vital targets for gene therapy, because they can
express neurotrophic factor genes and secrete neurotrophins
to induce neurite growth and/or enhance survival of spiral
ganglion cells, outcomes that could enhance the function of
the cochlear implant (Shibata et al., 2010; Wise et al., 2010).
Trans-RWM as a delivery route in humans and animals
The trans-RWM route of gene delivery requires a mini-
mally invasive surgical manipulation via the ear canal,
leading to no systemic side effects, minimal cochlear side
effects, and moderately efficient gene expression. The ap-
plication of the therapeutic reagent can be repeated if nec-
essary. However, although introducing reagents into the
middle-ear side of the RWM is possible, the membrane is
rather impermeable and, in most cases, does not allow sub-
stances to reach the perilymph on the other side (Goycoolea
and Lundman, 1997; Goycoolea, 2001). Some facilitating re-
agents, such as endotoxins or exotoxins (Ikeda and Mor-
izono, 1988; Selivanova et al., 2003), histamine
(Chandrasekhar et al., 2000), and benzyl alcohol, or suction
near the RWM (Mikulec et al., 2008), have been shown to
enhance RWM permeability and allow reagents to reach the
cochlear fluids. Many of the facilitating reagents have been
used for the purpose of delivering drugs such as dexa-
methasone or aminoglycosides. Our data together with those
of another group using Gelfoam ( Jero et al., 2001; Aarnisalo
et al., 2006) demonstrate the potential for enhanced efficiency
of transgene delivery by the trans-RWM route. When clinical
use of this method is considered, it will be necessary to
evaluate the effects of the procedure on the middle-ear tis-
sues and the outcome of gene expression of the therapeutic
genes on the RWM and surrounding middle-ear structures.
The choice of viral vectors for therapy is influenced by
several parameters. Adeno-associated viral vector (AAVs)
gene expression lasts for a long time and is ideal for secreting
neurotrophins or expressing other transgenes needed over a
long time. Additional studies are needed to determine the
influence of HA on the delivery of AAVs on the trans-RWM
delivery of genes in the cochlea. Some therapeutic applica-
tions do not need sustained gene expression over time, and
actually work better with a pulse of very efficient expression
that does not last for more than days or weeks. The use of
developmental genes for inducing transdifferentiation is an
example of short-term gene expression. The present study
uses adenovirus vectors, which are the vectors of choice for
transient gene expression. Future improvement in these
vectors will likely reduce their side effects and make them
more acceptable for clinical use.
Conclusions
In summary we present an atraumatic method to intro-
duce transgenes into cochlear cells. An important outcome in
this study is the wide delivery of transgenes into the cells
lining the scala tympani and moderate transduction in the
scala media of guinea pigs. No substantial side effects were
observed after surgery, and neither hair cell loss nor granu-
lation tissue proliferation was apparent in the whole-mount
analysis of the HA- and Ad-eGFP-treated ears, which indi-
cates that both had minimal ototoxicity.
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with low-frequency and Ménière’s-associated sudden senso-
rineural hearing loss. Otol. Neurotol. 26, 890–895.
Shibata, S.B., Cortez, S.R., Beyer, L.A., et al. (2010). Transgenic
BDNF induces nerve fiber regrowth into the auditory epithe-
lium in deaf cochleae. Exp. Neurol. 223, 464–472.
Staecker, H., Gabaizadeh, R., Federoff, H., and Van de Water,
T.R. (1998). Brain-derived neurotrophic factor gene therapy
prevents spiral ganglion degeneration after hair cell loss.
Otolaryngol. Head Neck Surg. 119, 7–13.
Stover, T., Yagi, M., and Raphael, Y. (1999). Cochlear gene
transfer: round window versus cochleostomy inoculation.
Hear. Res. 136, 124–130.
Van de Water, T.R., Staecker, H., Halterman, M.W., and Feder-
off, H.J. (1999). Gene therapy in the inner ear. Mechanisms and
clinical implications. Ann. N.Y. Acad. Sci. 884, 345–360.
Venail, F., Wang, J., Ruel, J., et al. (2007). Coxsackie adenovirus
receptor and amb3/amb5 integrins in adenovirus gene transfer
of rat cochlea. Gene Ther. 14, 30–37.
HA ENHANCES GENE DELIVERY INTO THE COCHLEA 309
Wang, H., Murphy, R., Taaffe, D., et al. (2011). Efficient cochlear
gene transfection in guinea-pigs with adeno-associated viral
vectors by partial digestion of round window membrane.
Gene Ther. [Epub ahead of print]
White, P.M., Doetzlhofer, A., Lee, Y.S., et al. (2006). Mammalian
cochlear supporting cells can divide and trans-differentiate
into hair cells. Nature 441, 984–987.
Wimmer, C., Mees, K., Stumpf, P., et al. (2004). Round window
application of D-methionine, sodium thiosulfate, brain-de-
rived neurotrophic factor, and fibroblast growth factor-2 in
cisplatin-induced ototoxicity. Otol. Neurotol. 25, 33–40.
Wise, A.K., Hume, C.R., Flynn, B.O., et al. (2010). Effects of lo-
calized neurotrophin gene expression on spiral ganglion
neuron resprouting in the deafened cochlea. Mol. Ther. 18,
1111–1122.
Yagi, M., Magal, E., Sheng, Z., et al. (1999). Hair cell protection
from aminoglycoside ototoxicity by adenovirus-mediated
overexpression of glial cell line-derived neurotrophic factor.
Hum. Gene Ther. 10, 813–823.
Yamasoba, T., and Dolan, D.F. (1997). Chronic strychnine ad-
ministration into the cochlea potentiates permanent threshold
shift following noise exposure. Hear. Res. 112, 13–20.
Address correspondence to:
Dr. Yehoash Raphael
Kresge Hearing Research Institute
Department of Otolaryngology
The University of Michigan
1150 W. Medical Center Dr.
Ann Arbor, MI 48109-5648
E-mail: yoash@umich.edu
Received for publication May 11, 2011;
accepted after revision November 9, 2011.
Published online: November 10, 2011.
310 SHIBATA ET AL.
This article has been cited by:
1. Hideto Fukui, Yehoash Raphael. 2013. Gene therapy for the inner ear. Hearing Research 297, 99-105. [CrossRef]
2. Yan Wei, Yong Fu, Shaosheng Liu, GuiHua Xia, Song Pan. 2013. Effect of lentiviruses carrying enhanced green fluorescent protein
injected into the scala media through a cochleostomy in rats. American Journal of Otolaryngology . [CrossRef]
